Vestion, Inc.

University of Miami

Duke University

The United States Government as Represented by the Department of Veterans Affairs

Longeveron, Inc.

Johns Hopkins University

Other

Joshua Hare

Konstantinos Chatzistergos

Jonathan S Stamler

Eric John Toone

Andrew V Schally

Norman L Block

Arnon Blum

Alan W Heldman

Rosemeire M Kanashiro-Takeuchi

Bettina Heidecker

Ana Marie Landin

Samirah Gomes

Rosemeire Miyuki Kanashiro Takeuchi

Michelle M Kittleson

Darcy L DiFede

Ian K Mcniece

Konstantinos E Hatzistergos

Erika B Rangel

Samirah A Gomes

Courtney Premer

Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.

Treatment of sexual dysfunction and improvement in sexual quality of life

The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.

Method of treating aging frailty in subjects with inflammaging using human mesenchymal stem cells

The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

Methods for obtaining cardiomyogenic precursor cells

The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies

Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

Therapy using cardiac stem cells and mesenchymal stem cells

Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.

Cardiac neural crest cells and methods of use thereof

Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

Method to amplify cardiac stem cells in vitro and in vivo

Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

GHRH agonists for the treatment of ischemic disorders

Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.

Cardiac stem cells and methods of identifying and using the same

A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

Growing community of inventors

Miami Beach, FL, United States of America

Joshua Hare